WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals in the ...

While GSK did not provide a specific reason for returning Wave Life Sciences’ WVE-006, the decision comes after the asset in ...

Wave Life Sciences has lost GSK as the partner for its RNA-editing drug for alpha-1 antitrypsin deficiency (AATD), just over ...

After GSK’s return of Wave Life Sciences’ WVE-006 as well as the mid-stage failure of Korro Bio’s candidate, the alpha-1 ...

Clear Street raised the firm’s price target on Wave Life Sciences (WVE) to $50 from $47 and keeps a Buy rating on the shares after GSK (GSK) returned the rights to WVE-006 for alpha1-antitrypsin ...

Alpha-1 antitrypsin deficiency (AATD) is a hereditary condition characterised by the misfolding of the alpha-1 antitrypsin (AAT) protein, resulting in its hepatic accumulation and compromised protease ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Least-squares mean percent differences in serum Z-AAT ...

Patients with lung disease are more likely to develop heart disease independent of any risk factors, according to new research. Boosting levels of a deficient protein has clear survival benefits for ...

Alpha-1 antitrypsin deficiency, AATD, is an inherited disease affecting the lung, liver, and, rarely, skin. Alpha-1 antitrypsin, AAT, is a protease inhibitor of the proteolytic enzyme elastase.

Patients with lung disease are more likely to develop heart disease independent of any risk factors, according to new research. Boosting levels of a deficient protein has clear survival benefits for ...